Skip To Main Content
Yingcheng Wu on Muck Rack

Yingcheng Wu

As seen in: ScienceDirect, Frontiers, Frontiers in Immunology, The BMJ, Science Magazine, Cell Press, Cell Reports, Cancer Discovery
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingcheng

Contact Yingcheng, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

OpenIO: An open framework for AI-native immunotherapy

|
By Yingcheng Wu, Hao Xiao, Nan Jiang, Will Hua, Jiaqiang Ma, Jiacheng Ge, Yong Liu, Zhongyue Zhang, Jack Chen, Ruofan Jin, Yingrui Wang, Jian Zhou, Jia Fan, Zaixiang Zheng, Lei Bai, Haifeng Ye, Qi Liu, Guoji Guo, Zaixi Zhang, Siqi Sun, Tiannan Guo, Shuangjia Zheng, Qiang Gao
| Cell Press Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Lesterhuis, W.J. ∙ Haanen, J.B.A.G. ∙ Punt, C.J.A. Cancer immunotherapy—revisited Nat. Rev. Drug Discov. 2011; 10:591-600 2. Nguyen, E. ∙ Poli, M. ∙ Durrant, M.G. ... Sequence modeling and design from molecular to genome scale with Evo Science. 2024; 386, eado9336 3. Cui, H. ∙ Wang, C. ∙ Maan, H. ... scGPT: toward building a foundation model for single-cell multi-omics using generative AI Nat. Methods. 2024; 21:1470-1480 4.
Open in Who Shared View Duplicates (2) Issue with article?

Editorial: Cancer metastases: mechanisms of tumor dissemination, formation of metastatic niche and anti-metastatic therapy

|
By Sergei Kusmartsev, Yingcheng Wu, Elena Voronov, Julia Schueler
| Frontiers in Immunology
Despite decades of progress in treating primary tumors, metastasis remains the final frontier and the central challenge in oncology. At late stages of cancer progression, primary localized tumors may metastasize to distant sites, including bones, lymph nodes, lungs, brain, liver, and other organs. Since current options to treat cancer metastases effectively are highly limited, cancer metastatic disease accounts for approximately 90% of cancer-related deaths.
Open in Who Shared Issue with article?

Pre-existing epigenetic state and differential NF-κB activation shape type 2 immune cell responses

|
By Yingcheng Wu, Qiang Gao, Athanasios Ziogas, Mihai G. Netea
| ScienceDirect Verified
Adaptive CD4+ T helper 2 (Th2) cells and group 2 innate lymphoid cells (ILC2s) are the main cell types that drive type 2 immune responses to provide protection against helminth infection or promote allergic inflammation.1 Th2 cells, which are primarily activated via engagement of the T cell receptor (TCR), act later during the immune response,2 while ILC2s, which lack TCR, are involved in the initial phase of the immune response.
Open in Who Shared Issue with article?
See all 16 articles